Allot Communications (ALLT) closed the last trading session at $9.46, gaining 0.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.5 indicates a 42.7% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $1.32. While the lowest estimate of $12.50 indicates a 32.1% increase from the current price level, the most optimistic anal ...

Core Viewpoint - Rezolute, Inc. (RZLT) shows potential for significant upside, with a mean price target of $15.22 indicating a 56.6% increase from its current price of $9.72 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $2.44, suggesting variability in analyst predictions [2] - The lowest estimate of $12.00 indicates a 23.5% increase, while the highest estimate of $20.00 suggests a potential surge of 105.8% [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price direction [9] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, three earnings estimates for RZLT have increased, leading to a 22.9% rise in the Zacks Consensus Estimate [12] - RZLT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - MBX Biosciences, Inc. (MBX) shares have increased by 57.1% in the past four weeks, closing at $34.49, with a potential upside of 80.6% based on Wall Street analysts' mean price target of $62.29 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $13.06, indicating variability among analysts; the lowest estimate is $45.00 (30.5% increase), while the highest is $80.00 (132% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, although it does not guarantee the stock will reach the average target [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about MBX's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] - The Zacks Consensus Estimate for the current year has risen by 2.9% over the past month, with three estimates increasing and no negative revisions [12] - MBX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead; empirical research suggests that analysts' price targets do not reliably predict actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - eToro Group Ltd. (ETOR) has shown a significant price increase of 13.3% over the past four weeks, with a mean price target of $60.06 indicating a potential upside of 43.1% from its current trading price of $41.97 [1] Price Targets and Analyst Consensus - The average price target for ETOR consists of 16 short-term estimates, ranging from a low of $46.00 to a high of $85.00, with a standard deviation of $11.1, suggesting variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 9.6%, while the highest suggests a remarkable upside of 102.5% [2] - A low standard deviation among price targets indicates a strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ETOR's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 6.2% over the past month, with two estimates increasing and no negative revisions [12] - ETOR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Jamie Cook from Truist Financial sets a price target of $612 for DE, indicating a potential increase of 30.25%.Advisors Asset Management Inc. reduces its stake by 30.8%, selling 3,753 shares.Brighton Jones LLC and Mackenzie Financial Corp increase their holdings, showing confidence in DE's growth potential.Deere & Company (NYSE: DE) is a leading manufacturer of agricultural, construction, and forestry machinery. Known for its iconic green and yellow equipment, Deere has a significant presence in the industr ...

Actuate Therapeutics, Inc. (ACTU) closed the last trading session at $6.9, gaining 4.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $21.67 indicates a 214.1% upside potential.The average comprises three short-term price targets ranging from a low of $20.00 to a high of $25.00, with a standard deviation of $2.89. While the lowest estimate indicates an increase of 189.9% from the ...

Group 1 - Shares of OppFi Inc. (OPFI) have increased by 1.5% over the past four weeks, closing at $9.76, with a mean price target of $14.5 indicating a potential upside of 48.6% [1] - The mean estimate includes three short-term price targets with a standard deviation of $1.32, where the lowest estimate of $13.50 suggests a 38.3% increase, and the highest estimate of $16.00 indicates a 63.9% increase [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 10.6% over the last 30 days, with two estimates moving higher and no negative revisions [12] - OPFI holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Rush Street Interactive, Inc. (RSI) shows potential for significant upside, with a mean price target of $23 indicating a 28.5% increase from its current price of $17.9 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $2.56, indicating variability among analysts [2] - The lowest estimate is $18.00, suggesting a 0.6% increase, while the highest estimate is $27.00, indicating a potential surge of 50.8% [2] - Analysts' price targets can be misleading, as they often set overly optimistic targets influenced by business relationships [7][8] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding RSI's earnings prospects supports the expectation of an upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 23.9%, with two estimates moving higher and no negative revisions [12] - RSI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not reliably indicate the extent of potential gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Rapport Therapeutics, Inc. (RAPP) shares have increased by 9.5% in the last four weeks, closing at $29.43, with a potential upside of 75% based on Wall Street analysts' mean price target of $51.5 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $34.00 to a high of $80.00, with a standard deviation of $13.2, indicating variability among analysts [2] - The lowest estimate suggests a 15.5% increase from the current price, while the highest estimate indicates a potential upside of 171.8% [2] Analyst Sentiment - Analysts show a consensus that RAPP will report better earnings than previously estimated, which supports the expectation of a stock price increase [4][11] - The Zacks Consensus Estimate for the current year has risen by 7.4% over the past month, with four estimates increasing and no negative revisions [12] Zacks Rank - RAPP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Price Movement Implications - While the consensus price target may not be a reliable indicator of the extent of RAPP's potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Hinge Health Inc. (HNGE) has shown a 0.9% increase in stock price over the past four weeks, closing at $50.05, with analysts suggesting a potential upside of 29.6% based on a mean price target of $64.86 [1][11]. Price Targets - The average of 14 short-term price targets ranges from a low of $56.00 to a high of $72.00, with a standard deviation of $4.66, indicating a relatively high agreement among analysts [2][9]. - The lowest estimate suggests an 11.9% increase from the current price, while the highest estimate indicates a 43.9% upside [2]. Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with positive stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has increased by 4.6% over the past month, with seven estimates revised upward and no negative revisions [12]. Zacks Rank - HNGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the exact price movement, it does provide a useful guide for potential price direction [14].